Pear Therapeutics’ reSET and reSET-O prescription digital therapeutics can be found to Florida’s 5 million Medicaid sufferers through its Most well-liked Drug Listing as of this month.
Pear’s reSET, a cell software used to assist deal with substance abuse, acquired FDA De Novo clearance in 2017. The Boston-based firm’s reSET-O, used for opioid use dysfunction, acquired 510(k) clearance in 2018.
“The unmet want in dependancy throughout the U.S. is big, and Florida represents an essential step in how we’re serving to an increasing number of sufferers by working with states to offer coated entry to our merchandise,” Julia Strandberg, chief industrial officer of Pear Therapeutics, mentioned in an announcement.
THE LARGER TREND
In November, Pear entered right into a contract with the Wisconsin Department of Health Services to supply its reSET and reSET-O prescription digital therapeutics to collaborating suppliers throughout the state’s outpatient therapy settings, together with packages that present prescriptions for buprenorphine, a drugs used to deal with opioid dependence.
Earlier this month, Spero Health introduced its 99 outpatient substance abuse facilities all through Kentucky, Ohio, Indiana, Tennessee, Virginia and West Virginia would acquire entry to reSET and reSET-O.
The corporate was additionally awarded a contract from the California Division of Healthcare Providers to help the implementation of a pilot program that gives motivational incentives to people with stimulant use dysfunction.
The publicly-traded firm wasn’t resistant to the various layoffs seen all through the digital well being sector final summer time.
In July, Pear laid off roughly 25 of its staff, making up about 9% of its full-time workforce, as a result of bigger financial surroundings and the necessity to restructure operations to slender its short-term enterprise focus.
The layoff announcement got here three months after Pear launched a program to offer its reSET and reSET-O offerings via telehealth providers. The primary was Pursue Care, which focuses on dependancy medication.
